US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% SNDK $1,719.99 ▲+0.00% NVDA $233.95 ▲+0.00% SPCX $158.96 ▲+0.00% AMD $633.91 ▲+0.00% MSTR $160.01 ▲+0.00% ASML $1,867.31 ▲+0.00%
FinancialContent

Boundless Bio, Inc. - Common Stock (NQ:BOLD)

2.620 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Boundless Bio, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
Boundless Bio to Participate in the Leerink Global Healthcare Conference
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer
- Dr. Doebele has over 15 years of oncology drug development experience as a public company Chief Medical Officer and clinical researcher at leading cancer centers - 
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
BOLD Stock Earnings: Boundless Bio Reported Results for Q1 2024 ↗
Boundless Bio just reported results for the first quarter of 2024. 
Via InvestorPlace
News headline image
Boundless Bio Announces Pipeline and Leadership Updates
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
Boundless Bio to Participate in the Piper Sandler Healthcare Conference
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
Boundless Bio to Participate in the 2024 Guggenheim Global Healthcare Conference
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
Boundless Bio Announces Departure of Chief Financial Officer
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
Boundless Bio to Participate in the 2024 Cantor Global Healthcare Conference
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
BOLD Stock Earnings: Boundless Bio Beats EPS for Q2 2024 ↗
BOLD stock results show that Boundless Bio beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Boundless Bio
Via Business Wire
News headline image
Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights
From Boundless Bio
Via Business Wire
News headline image
Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024
From Boundless Bio
Via Business Wire
News headline image
Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications
From Boundless Bio
Via Business Wire
News headline image
Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024
From Boundless Bio
Via Business Wire
News headline image
Bayer-Backed Boundless Bio Falls After IPO ↗
Shares of Boundless Bio fell almost 10% after raising about $100 million in the company's initial public offering. Bayer is one of the biggest investors for the therapeutics company. 
Via Talk Markets
< Previous 1 2 Next >